{
  "id": 1289945,
  "title": "Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year",
  "url": "https://urgent.news/2026/08/16/neuroscience-is-becoming-abbvies-quiet-powerhouse-and-management-now",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-16T14:43:00.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/08/16/neuroscience-is-becoming-abbvies-quiet-powerhouse/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "AbbVie, once renowned for its immunology-focused portfolio, has now expanded into the neuroscience sector, marking a significant shift in its business strategy. The company's neuroscience portfolio is on track to generate approximately $12.7 billion in revenue by 2026, a figure representing a $100 million increase from its guidance following a robust first half of the year. This projected growth rate remains impressive considering the neuroscience segment generated $10.8 billion in revenue last year and continues to expand at a double-digit pace.\n\nUnlike many pharmaceutical franchises reliant on a single blockbuster drug, AbbVie's neuroscience business has become increasingly diversified. During the second quarter alone, the revenue from the sector climbed by 20.3% year over year, reaching $3.23 billion. Key contributors to this surge include Vraylar, a drug treating schizophrenia and bipolar disorder, which brought in $1.07 billion. Therapeutic Botox contributed $1.04 billion, while migraine medications Ubrelvy and Qulipta combined for $742 million in quarterly sales. Additionally, Vyalev, a therapy for Parkinson's disease, added another $256 million to the portfolio.",
  "summary": "AbbVie has another blockbuster business emerging.",
  "key_points": [
    "AbbVie expanding into neuroscience sector, aiming for $12.7B revenue by 2026",
    "Neuroscience portfolio generated $10.8B last year, now projected to grow 20.3% QoQ",
    "Vraylar, Ubrelvy, Qulipta, and Vyalev drive revenue growth in neuroscience segment"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Nasdaq Markets",
        "title": "Neuroscience Is Becoming AbbVie's Quiet Powerhouse -- and Management Now Sees $12.7 Billion in Sales This Year",
        "url": "https://urgent.news/2026/08/16/neuroscience-is-becoming-abbvies-quiet-powerhouse-and-management-now-1298747",
        "published": "2026-08-16T15:03:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}